Brachytherapy
Volume 8, Issue 1 , Page 8 , January 2009

Rebuttal to Dr. Bice

References 

  1. Sahgal A, Jabbari S, Chen J, et al. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using (131)Cs and (125)I for prostate permanent implant brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72:247–254
  2. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA. 2008;299:2789–2791
  3. Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008;112:2195–2201
  4. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173–181

PII: S1538-4721(08)00658-2

doi: 10.1016/j.brachy.2008.11.004

Brachytherapy
Volume 8, Issue 1 , Page 8 , January 2009

Article Tools